Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Jul;2(4):503–505. doi: 10.1128/cdli.2.4.503-505.1995

Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias.

I Munno 1, M Marinaro 1, A Gesario 1, B Cannuscio 1, Y Michel 1, E Paulling 1
PMCID: PMC170190  PMID: 7583935

Abstract

In this report, we have evaluated the immunological effects following administration of alpha interferon (IFN-alpha) in combination with thymostimulin (TP-1), as well as of IFN-alpha and TP-1 alone in patients with neoplasias who underwent surgery and were subsequently treated with conventional chemotherapy. Data suggest that the combination of IFN-alpha and TP-1 is the most effective in the up-regulation of some immune parameters such as the CD4(+)-CD8+ cell-dependent antibacterial activity. Since this immune function plays an important role in the host protection against different targets such as invading microorganisms and/or neoplastic cells, the administration of TP-1-IFN-alpha is advisable for patients with neoplasias under chemotherapy.

Full Text

The Full Text of this article is available as a PDF (167.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonaci S., Tortorella C., De Simone C., Jirillo E. Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes. Int Rev Immunol. 1990;6(4):237–245. doi: 10.3109/08830189009056634. [DOI] [PubMed] [Google Scholar]
  2. Borden E. C., Balkwill F. R. Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer. 1984 Feb 1;53(3 Suppl):783–789. doi: 10.1002/1097-0142(19840201)53:3+<783::aid-cncr2820531329>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  3. Bubeník J., Kieler J., Tromholt V., Hermann G., Jandlová T. Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol Lett. 1988 Jun;18(2):115–118. doi: 10.1016/0165-2478(88)90050-8. [DOI] [PubMed] [Google Scholar]
  4. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  5. Castello G., Lerza R., Mencoboni M., Cavallini D., Flego G., Cerruti A., Ballarino P., Bogliolo G., Pannacciulli I. Cisplatin, 5-fluorouracil and alpha interferon in non small cell lung carcinoma: a toxicity study. Anticancer Res. 1994 Mar-Apr;14(2B):621–625. [PubMed] [Google Scholar]
  6. Fagiolo U., Amadori A., Borghesan F., Zamarchi R., Veronese M. L., De Silvestro G., Passarella E., Crepaldi G. Immune dysfunction in the elderly: effect of thymic hormone administration on several in vivo and in vitro immune function parameters. Aging (Milano) 1990 Dec;2(4):347–355. doi: 10.1007/BF03323947. [DOI] [PubMed] [Google Scholar]
  7. Gresser I. Antitumour effects of interferons: past, present and future. Br J Haematol. 1991 Oct;79 (Suppl 1):1–5. doi: 10.1111/j.1365-2141.1991.tb08108.x. [DOI] [PubMed] [Google Scholar]
  8. Kase S., Kubota T., Watanabe M., Furukawa T., Tanino H., Ishibiki K., Teramoto T., Kitajima M. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res. 1993 Mar-Apr;13(2):369–373. [PubMed] [Google Scholar]
  9. Kirkwood J. M. Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct;18(5 Suppl 7):83–90. [PubMed] [Google Scholar]
  10. Kreuser E. D., Wadler S., Thiel E. Interactions between cytokines and cytotoxic drugs: putative molecular mechanisms in experimental hematology and oncology. Semin Oncol. 1992 Apr;19(2 Suppl 4):1–7. [PubMed] [Google Scholar]
  11. Mandell G. L., Hook E. W. Leukocyte function in chronic granulomatous disease of childhood. Studies on a seventeen year old boy. Am J Med. 1969 Sep;47(3):473–486. doi: 10.1016/0002-9343(69)90231-9. [DOI] [PubMed] [Google Scholar]
  12. Mustacchi G., Pavesi L., Milani S., Iaffaioli V., Caraco A., Comella G., Contu A., Farris A., Attado-Parinello G., Narcisi M. High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial. Anticancer Res. 1994 Mar-Apr;14(2B):617–619. [PubMed] [Google Scholar]
  14. Rabinowich H., Vitolo D., Altarac S., Herberman R. B., Whiteside T. L. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. J Immunol. 1992 Jul 1;149(1):340–349. [PubMed] [Google Scholar]
  15. Repetto L., Venturino A., Simoni C., Rosso M., Melioli G., Rosso R. Interferons in the treatment of advanced breast cancer. J Biol Regul Homeost Agents. 1993 Oct-Dec;7(4):109–114. [PubMed] [Google Scholar]
  16. Schindler L., Leroux M., Zimmermann G. F., Betzler M., Kirchner H. Reversal of defective lymphoproliferation in postoperative patients with colon cancer. J Cancer Res Clin Oncol. 1987;113(2):166–170. doi: 10.1007/BF00391440. [DOI] [PubMed] [Google Scholar]
  17. Semino C., Ferlazzo G., Pietra G., Pasquetti W., Repetto L., Rosso R., Mariani M., Melioli G. Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells. J Biol Regul Homeost Agents. 1993 Jul-Sep;7(3):99–105. [PubMed] [Google Scholar]
  18. Serrate S. A., Schulof R. S., Leondaridis L., Goldstein A. L., Sztein M. B. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol. 1987 Oct 1;139(7):2338–2343. [PubMed] [Google Scholar]
  19. Shoham J., Eshel I., Aboud M., Salzberg S. Thymic hormonal activity on human peripheral blood lymphocytes in vitro. II. Enhancement of the production of immune interferon by activated cells. J Immunol. 1980 Jul;125(1):54–58. [PubMed] [Google Scholar]
  20. Stevenson H., Tsang K. Y. Tumor immunology. Immunol Ser. 1993;58:497–515. [PubMed] [Google Scholar]
  21. Teichmann J. V., Ludwig W. D., Thiel E. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk Res. 1992;16(3):287–298. doi: 10.1016/0145-2126(92)90067-h. [DOI] [PubMed] [Google Scholar]
  22. Zagury D., Fouchard M., Vol J. C., Cattan A., Leibowitch J., Feldman M., Sarin P. S., Gallo R. C. Detection of infectious HTLV-III/LAV virus in cell-free plasma from AIDS patients. Lancet. 1985 Aug 31;2(8453):505–506. doi: 10.1016/s0140-6736(85)90442-8. [DOI] [PubMed] [Google Scholar]
  23. Zielinski C. C., Mueller C., Tyl E., Tichatschek E., Kubista E., Spona J. Impaired production of tumor necrosis factor in breast cancer. Cancer. 1990 Nov 1;66(9):1944–1948. doi: 10.1002/1097-0142(19901101)66:9<1944::aid-cncr2820660916>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES